Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High – Should You Buy?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) hit a new 52-week high during trading on Tuesday . The company traded as high as $41.55 and last traded at $41.07, with a volume of 253413 shares traded. The stock had previously closed at $38.94.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. HC Wainwright lifted their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Finally, Mizuho lifted their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $43.40.

Enliven Therapeutics Price Performance

The firm’s 50 day moving average is $29.97 and its two-hundred day moving average is $23.82. The firm has a market capitalization of $2.56 billion, a P/E ratio of -22.99 and a beta of 0.26.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Activity

In related news, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the sale, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Anish Patel sold 48,300 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the sale, the chief operating officer owned 215,011 shares in the company, valued at approximately $6,018,157.89. This trade represents a 18.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 232,180 shares of company stock valued at $6,217,033. Company insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP grew its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares in the last quarter. TCG Crossover Management LLC bought a new stake in shares of Enliven Therapeutics during the second quarter worth $9,990,000. Duquesne Family Office LLC grew its stake in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after buying an additional 484,405 shares during the last quarter. Spruce Street Capital LP acquired a new stake in shares of Enliven Therapeutics during the fourth quarter valued at about $6,870,000. Finally, Polar Capital Holdings Plc raised its stake in shares of Enliven Therapeutics by 13.5% during the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after acquiring an additional 418,673 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.